JP2014518543A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014518543A5 JP2014518543A5 JP2013555559A JP2013555559A JP2014518543A5 JP 2014518543 A5 JP2014518543 A5 JP 2014518543A5 JP 2013555559 A JP2013555559 A JP 2013555559A JP 2013555559 A JP2013555559 A JP 2013555559A JP 2014518543 A5 JP2014518543 A5 JP 2014518543A5
- Authority
- JP
- Japan
- Prior art keywords
- group
- pharmaceutically acceptable
- alkyl
- acceptable salt
- optionally
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000003839 salts Chemical class 0.000 claims 14
- 150000001875 compounds Chemical class 0.000 claims 13
- 125000001424 substituent group Chemical group 0.000 claims 12
- 125000000217 alkyl group Chemical group 0.000 claims 11
- 125000000753 cycloalkyl group Chemical group 0.000 claims 10
- 229910052739 hydrogen Inorganic materials 0.000 claims 10
- 239000001257 hydrogen Substances 0.000 claims 10
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims 10
- 125000003710 aryl alkyl group Chemical group 0.000 claims 9
- 125000003118 aryl group Chemical group 0.000 claims 9
- 125000001072 heteroaryl group Chemical group 0.000 claims 9
- 125000004446 heteroarylalkyl group Chemical group 0.000 claims 9
- 125000003342 alkenyl group Chemical group 0.000 claims 7
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims 7
- 125000005885 heterocycloalkylalkyl group Chemical group 0.000 claims 7
- 125000004183 alkoxy alkyl group Chemical group 0.000 claims 5
- 239000008194 pharmaceutical composition Substances 0.000 claims 5
- 125000004429 atom Chemical group 0.000 claims 4
- 125000002619 bicyclic group Chemical group 0.000 claims 4
- -1 carbocycle Chemical group 0.000 claims 4
- 125000004093 cyano group Chemical group *C#N 0.000 claims 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 4
- 125000002950 monocyclic group Chemical group 0.000 claims 4
- 125000000169 tricyclic heterocycle group Chemical group 0.000 claims 4
- 125000003545 alkoxy group Chemical group 0.000 claims 3
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 3
- 229910052736 halogen Inorganic materials 0.000 claims 3
- 150000002367 halogens Chemical class 0.000 claims 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 3
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims 3
- 102000000393 Ghrelin Receptors Human genes 0.000 claims 2
- 108010016122 Ghrelin Receptors Proteins 0.000 claims 2
- UFWIBTONFRDIAS-UHFFFAOYSA-N Naphthalene Chemical group C1=CC=CC2=CC=CC=C21 UFWIBTONFRDIAS-UHFFFAOYSA-N 0.000 claims 2
- 206010033799 Paralysis Diseases 0.000 claims 2
- 206010054048 Postoperative ileus Diseases 0.000 claims 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 2
- 125000001309 chloro group Chemical group Cl* 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 125000001153 fluoro group Chemical group F* 0.000 claims 2
- 230000002496 gastric effect Effects 0.000 claims 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 2
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 2
- WGIAKIIMCPKJQN-SFVWDYPZSA-N 3-[(1s)-1-(2,3-dichloro-4-methoxyphenyl)ethyl]-1-methyl-1-(1,3,3-trimethylpiperidin-4-yl)urea Chemical compound ClC1=C(Cl)C(OC)=CC=C1[C@H](C)NC(=O)N(C)C1C(C)(C)CN(C)CC1 WGIAKIIMCPKJQN-SFVWDYPZSA-N 0.000 claims 1
- 208000030507 AIDS Diseases 0.000 claims 1
- 208000000103 Anorexia Nervosa Diseases 0.000 claims 1
- 206010006895 Cachexia Diseases 0.000 claims 1
- 206010007559 Cardiac failure congestive Diseases 0.000 claims 1
- 206010010774 Constipation Diseases 0.000 claims 1
- 208000007882 Gastritis Diseases 0.000 claims 1
- 206010019280 Heart failures Diseases 0.000 claims 1
- 206010028813 Nausea Diseases 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 208000030053 Opioid-Induced Constipation Diseases 0.000 claims 1
- 208000002193 Pain Diseases 0.000 claims 1
- 201000010769 Prader-Willi syndrome Diseases 0.000 claims 1
- 208000001647 Renal Insufficiency Diseases 0.000 claims 1
- 206010047700 Vomiting Diseases 0.000 claims 1
- 230000032683 aging Effects 0.000 claims 1
- 125000001246 bromo group Chemical group Br* 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 125000002837 carbocyclic group Chemical group 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 201000006549 dyspepsia Diseases 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 208000021302 gastroesophageal reflux disease Diseases 0.000 claims 1
- 230000005176 gastrointestinal motility Effects 0.000 claims 1
- 125000004438 haloalkoxy group Chemical group 0.000 claims 1
- 208000002551 irritable bowel syndrome Diseases 0.000 claims 1
- 201000006370 kidney failure Diseases 0.000 claims 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 230000008693 nausea Effects 0.000 claims 1
- 230000036407 pain Effects 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 1
- 238000006467 substitution reaction Methods 0.000 claims 1
- 230000008673 vomiting Effects 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/CN2011/000298 WO2012113103A1 (en) | 2011-02-25 | 2011-02-25 | Asymmetric ureas and medical uses thereof |
| CNPCT/CN2011/00298 | 2011-02-25 | ||
| US201161466070P | 2011-03-22 | 2011-03-22 | |
| US61/466,070 | 2011-03-22 | ||
| PCT/US2012/026315 WO2012116176A2 (en) | 2011-02-25 | 2012-02-23 | Asymmetric ureas and medical uses thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014518543A JP2014518543A (ja) | 2014-07-31 |
| JP2014518543A5 true JP2014518543A5 (enExample) | 2015-03-19 |
| JP6077468B2 JP6077468B2 (ja) | 2017-02-08 |
Family
ID=46719417
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013555559A Active JP6077468B2 (ja) | 2011-02-25 | 2012-02-23 | 不斉尿素及びその医学的用途 |
Country Status (41)
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2012113103A1 (en) | 2011-02-25 | 2012-08-30 | Helsinn Healthcare S.A. | Asymmetric ureas and medical uses thereof |
| MX370720B (es) | 2012-12-21 | 2019-12-20 | Aveo Pharmaceuticals Inc | Anticuerpos anti-gdf15. |
| TWI703130B (zh) * | 2014-03-07 | 2020-09-01 | 瑞士商赫爾辛保健股份有限公司 | 對位取代的不對稱脲及其醫療用途 |
| RU2686317C2 (ru) * | 2015-04-24 | 2019-04-25 | Федеральное государственное бюджетное научное учреждение "Научно-исследовательский институт фармакологии имени В.В. Закусова" | Замещенные 1,2,5-триметил- и 2,2,6,6-тетраметил-4-аминопиперидины, обладающие антиишемическим действием |
| KR102640774B1 (ko) | 2016-03-22 | 2024-02-26 | 헬신 헬쓰케어 에스.에이. | 벤젠술포닐-비대칭 우레아 및 그의 의학적 용도 |
| US11071738B2 (en) | 2017-08-07 | 2021-07-27 | Hiroshima University | Therapeutic agent for fatty liver diseases and therapeutic agent for adiposity |
| WO2019040104A2 (en) | 2017-08-21 | 2019-02-28 | Acadia Pharmaceuticals Inc. | COMPOUNDS, RELATED SALTS AND METHODS OF TREATING DISEASES |
| AU2018321546B2 (en) | 2017-08-21 | 2022-09-08 | Acadia Pharmaceuticals Inc. | Compounds, salts thereof and methods for treatment of diseases |
| IL275153B2 (en) | 2017-12-11 | 2024-12-01 | Helsinn Healthcare Sa | Fumarate salts of (R)-3-(1-(2, 3-dichloro-4-(pyrazin-2-yl)phenyl)-2,2,2-trifluoroethyl)-1-methyl-1-(1-methylpiperidin-4-yl)urea, methods for their preparation and use |
| EP3542799A1 (en) | 2018-03-22 | 2019-09-25 | Helsinn Healthcare SA | New centrally-active ghrelin agonist and medical uses thereof |
| CR20230467A (es) | 2021-03-10 | 2024-02-20 | Jnana Therapeutics Inc | Inhibidores de molécula pequeña de la función de slc6a19 de mamífero |
| JP2024520755A (ja) | 2021-06-02 | 2024-05-24 | ヘルシン ヘルスケア ソシエテ アノニム | 変力剤として使用するためのピペリジン尿素誘導体 |
| EP4404926A4 (en) * | 2021-09-22 | 2025-08-13 | Univ Duke | COMPOSITIONS FOR THE TREATMENT OF FOOD ADDICTION AND CHEMICAL DEPENDENCE AND METHODS OF MAKING AND USING THE SAME |
| WO2024158862A1 (en) * | 2023-01-25 | 2024-08-02 | University Of North Texas Health Science Center | Thiourea antioxcompounds with neuroprotective activity |
Family Cites Families (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5285174A (en) * | 1976-01-05 | 1977-07-15 | Yoshitomi Pharmaceut Ind Ltd | Novel urea or thiourea derivatives |
| AU7545894A (en) | 1993-09-02 | 1995-03-22 | Yamanouchi Pharmaceutical Co., Ltd. | Carbamate derivative and medicine containing the same |
| AU3785597A (en) | 1996-08-14 | 1998-03-06 | Takeda Chemical Industries Ltd. | Cyclic urea compounds, their production and use as herbicides |
| US6399619B1 (en) | 1999-04-06 | 2002-06-04 | Merck & Co., Inc. | Pyrrolidine modulators of chemokine receptor activity |
| PT1263729E (pt) * | 2000-03-06 | 2007-03-30 | Acadia Pharm Inc | Compostos azacílclicos para utilização no tratamento de doenças relacionadas com a serotonina |
| GB0011838D0 (en) * | 2000-05-17 | 2000-07-05 | Astrazeneca Ab | Chemical compounds |
| US20030022891A1 (en) * | 2000-12-01 | 2003-01-30 | Anandan Palani | MCH antagonists and their use in the treatment of obesity |
| JP2004520423A (ja) | 2001-03-01 | 2004-07-08 | アストラゼネカ・アクチエボラーグ | Ｃｃｒ５モジュレーターとしてのｎ−ピペリジニル化合物 |
| GB0107228D0 (en) | 2001-03-22 | 2001-05-16 | Astrazeneca Ab | Chemical compounds |
| US6673829B2 (en) * | 2001-09-14 | 2004-01-06 | Novo Nordisk A/S | Aminoazetidine,-pyrrolidine and -piperidine derivatives |
| SE0103818D0 (sv) | 2001-11-15 | 2001-11-15 | Astrazeneca Ab | Chemical compounds |
| SE0200919D0 (sv) | 2002-03-25 | 2002-03-25 | Astrazeneca Ab | Chemical compounds |
| CA2498272A1 (en) * | 2002-09-11 | 2004-03-25 | Merck & Co., Inc. | Piperazine urea derivatives as melanocortin-4 receptor agonists |
| AU2003284402A1 (en) | 2002-11-15 | 2004-06-15 | Yamanouchi Pharmaceutical Co., Ltd. | Antagonist to melanin-concentrating hormone receptor |
| EP1640361B9 (en) * | 2003-06-30 | 2015-11-04 | Sumitomo Chemical Company, Limited | Asymmetric urea compounds and process for producing asymmetric compounds by asymmetric conjugate addition reaction using the same as catalyst |
| US7115767B2 (en) * | 2003-07-18 | 2006-10-03 | Abbott Laboratories | Tetraline derivatives as ghrelin receptor modulators |
| ATE371649T1 (de) * | 2004-02-10 | 2007-09-15 | Janssen Pharmaceutica Nv | Pyridazinonharnstoffe als antagonisten von a4- integrinen |
| US20050261278A1 (en) * | 2004-05-21 | 2005-11-24 | Weiner David M | Selective serotonin receptor inverse agonists as therapeutics for disease |
| GB0412865D0 (en) | 2004-06-09 | 2004-07-14 | Glaxo Group Ltd | Chemical compounds |
| SE0401657D0 (sv) | 2004-06-24 | 2004-06-24 | Astrazeneca Ab | Chemical compounds |
| SE0401971D0 (sv) * | 2004-08-02 | 2004-08-02 | Astrazeneca Ab | Piperidne derivatives |
| AU2005272627A1 (en) * | 2004-08-13 | 2006-02-23 | Amgen Inc. | Substituted benzofused heterocycles |
| CA2575764A1 (en) * | 2004-10-27 | 2006-05-11 | Neurogen Corporation | Diaryl ureas as cb1 antagonists |
| WO2006068594A1 (en) | 2004-12-21 | 2006-06-29 | Astrazeneca Ab | HETEROCYCLIC MCHr1 ANTAGONISTS AND THEIR USE IN THERAPY |
| US7829589B2 (en) | 2005-06-10 | 2010-11-09 | Elixir Pharmaceuticals, Inc. | Sulfonamide compounds and uses thereof |
| EP1931633A2 (en) * | 2005-09-05 | 2008-06-18 | Ranbaxy Laboratories Limited | Derivatives of 3-azabicyclo[3.1.0]hexane as dipeptidyl peptidase-iv inhibitors |
| KR20080076916A (ko) * | 2005-11-01 | 2008-08-20 | 트랜스테크 파르마, 인크. | 치환된 아미드의 약학적 사용 |
| AR058277A1 (es) * | 2005-12-09 | 2008-01-30 | Solvay Pharm Gmbh | N- sulfamoil - piperidin - amidas, composiciones farmaceuticas que las comprenden y procedimiento para su preparacion |
| EP2043634A2 (en) | 2006-07-12 | 2009-04-08 | Merck & Co., Inc. | Substituted pyrazoles as ghrelin receptor antagonists |
| JP2008042298A (ja) | 2006-08-02 | 2008-02-21 | Olympus Corp | 固体撮像装置 |
| GB0701992D0 (en) | 2007-02-02 | 2007-03-14 | 7Tm Pharma As | Grehlin Receptor Modulators |
| US20080280886A1 (en) * | 2007-05-08 | 2008-11-13 | Auspex Pharmaceuticals, Inc. | Substituted ureas |
| GB0710863D0 (en) | 2007-06-06 | 2007-07-18 | Glaxo Group Ltd | Novel compounds |
| GB0710865D0 (en) | 2007-06-06 | 2007-07-18 | Glaxo Group Ltd | Novel compounds |
| EP2187746A4 (en) | 2007-08-06 | 2011-01-19 | Univ California | PREPARATION OF NEW 1,3-SUBSTITUTED UREASES AS A HOLDER OF SOLUBLE EPOXY HYDROLASE |
| HUE037639T2 (hu) * | 2007-09-21 | 2018-09-28 | Acadia Pharm Inc | Pimavanszerin együttes beadása más szerekkel |
| UA100527C2 (en) * | 2007-10-10 | 2013-01-10 | Астразенека Аб | Benzothiazoles as ghrelin receptor modulators |
| WO2009092293A1 (en) | 2008-01-18 | 2009-07-30 | Shanghai Targetdrug Co., Ltd. | Pyrollidine-based compounds |
| WO2009089659A1 (en) | 2008-01-18 | 2009-07-23 | Shanghai Targetdrug Co., Ltd. | Pyrollidine-based compounds |
| USRE49686E1 (en) * | 2008-09-19 | 2023-10-10 | Takeda Pharmaceutical Company Limited | Nitrogen-containing heterocyclic compound and use of same |
| WO2010111353A1 (en) * | 2009-03-25 | 2010-09-30 | Acadia Pharmaceuticals, Inc. | N-substituted piperidine derivatives as serotonin receptor agents |
| WO2011060397A1 (en) * | 2009-11-16 | 2011-05-19 | Schering Corporation | Substituted amino heterocycles useful as hiv antagonists |
| WO2012113103A1 (en) * | 2011-02-25 | 2012-08-30 | Helsinn Healthcare S.A. | Asymmetric ureas and medical uses thereof |
-
2011
- 2011-02-25 WO PCT/CN2011/000298 patent/WO2012113103A1/en not_active Ceased
-
2012
- 2012-02-23 KR KR1020137025184A patent/KR20140014186A/ko not_active Withdrawn
- 2012-02-23 JP JP2013555559A patent/JP6077468B2/ja active Active
- 2012-02-23 PL PL12749383T patent/PL2678017T3/pl unknown
- 2012-02-23 PH PH1/2013/501757A patent/PH12013501757A1/en unknown
- 2012-02-23 ES ES12749383.1T patent/ES2628386T3/es active Active
- 2012-02-23 MA MA36252A patent/MA34968B1/fr unknown
- 2012-02-23 KR KR1020187017910A patent/KR101907573B1/ko active Active
- 2012-02-23 CA CA2820767A patent/CA2820767C/en active Active
- 2012-02-23 HU HUE12749383A patent/HUE035039T2/en unknown
- 2012-02-23 ME MEP-2017-123A patent/ME02845B/me unknown
- 2012-02-23 PE PE2013001934A patent/PE20141000A1/es active IP Right Grant
- 2012-02-23 GE GEAP201213239A patent/GEP20156319B/en unknown
- 2012-02-23 EA EA201300946A patent/EA027374B1/ru unknown
- 2012-02-23 SI SI201230981A patent/SI2678017T1/sl unknown
- 2012-02-23 UA UAA201311289A patent/UA113510C2/uk unknown
- 2012-02-23 PT PT127493831T patent/PT2678017T/pt unknown
- 2012-02-23 AP AP2013007123A patent/AP3768A/en active
- 2012-02-23 CN CN201611088800.9A patent/CN106995403B/zh active Active
- 2012-02-23 BR BR112013021566-6A patent/BR112013021566B1/pt active IP Right Grant
- 2012-02-23 SM SM20170407T patent/SMT201700407T1/it unknown
- 2012-02-23 RS RS20170546A patent/RS56033B1/sr unknown
- 2012-02-23 CN CN201280008805.XA patent/CN103874492B/zh active Active
- 2012-02-23 DK DK12749383.1T patent/DK2678017T3/en active
- 2012-02-23 EP EP12749383.1A patent/EP2678017B1/en active Active
- 2012-02-23 HR HRP20170997TT patent/HRP20170997T1/hr unknown
- 2012-02-23 WO PCT/US2012/026315 patent/WO2012116176A2/en not_active Ceased
- 2012-02-23 MX MX2013006974A patent/MX347587B/es active IP Right Grant
- 2012-02-23 AU AU2012220531A patent/AU2012220531B2/en active Active
- 2012-02-23 LT LTEP12749383.1T patent/LT2678017T/lt unknown
- 2012-02-23 SG SG2013056775A patent/SG192138A1/en unknown
- 2012-02-23 MY MYPI2013003013A patent/MY164354A/en unknown
- 2012-02-24 TW TW101106171A patent/TWI579273B/zh active
- 2012-02-24 US US13/404,165 patent/US8658797B2/en active Active
- 2012-02-24 AR ARP120100611A patent/AR085398A1/es active IP Right Grant
-
2013
- 2013-08-13 IL IL227941A patent/IL227941A/en active IP Right Grant
- 2013-08-15 NI NI201300070A patent/NI201300070A/es unknown
- 2013-08-16 TN TNP2013000346A patent/TN2013000346A1/fr unknown
- 2013-08-21 CL CL2013002412A patent/CL2013002412A1/es unknown
- 2013-08-23 DO DO2013000195A patent/DOP2013000195A/es unknown
- 2013-09-19 ZA ZA2013/07071A patent/ZA201307071B/en unknown
- 2013-09-24 EC EC2013012893A patent/ECSP13012893A/es unknown
- 2013-09-24 CO CO13226995A patent/CO6771450A2/es unknown
-
2014
- 2014-01-08 US US14/150,360 patent/US9751836B2/en active Active
-
2017
- 2017-06-19 CY CY20171100635T patent/CY1118947T1/el unknown
- 2017-07-30 US US15/663,761 patent/US10407390B2/en active Active